The Integrated Forecasting and Analysis Tool   Login Now

Accentia Biopharmaceuticals

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for Accentia Biopharmaceuticals are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on Accentia Biopharmaceuticals, or on any other Company covered by EvaluatePharma® Contact Us today.

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) Accentia Biopharmaceuticals 1 AllerNase Respiratory Corticoids Corticosteroid Filed   2 BiovaxID Oncology & Immunomodulators Immunostimulants Cancer vaccine Phase III   - SinuNase Systemic Anti-infectives Anti-fungals Polyene Phase III

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Accentia Biopharmaceuticals   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 49 49        PE Ratio (diluted) - Normalised (x) (0.1) (0.7)        Valuing the Enterprise        Enterprise Value 100 100        Free Cash Flow (Pre-Dividends) (36) (26)        FCF Yield (%) (35.6%) (26.4%)    Forecast Financials   Income Statement      Total Revenues 25 25      Cost of Goods Sold (8) (8)      S,G & A (36) (37)      R&D (11) (15)      Other Income/ Expense - Net (3) 0      EBIT - Normalised (33) (35)      Net Interest & Financial Items (4) (7)      Pre-tax Profits - Normalised (37) (42)      Exceptionals (7) (2)      Income Before Taxes (44) (43)      Tax 0 0      Tax Rate (%) 0.0% 0.0%      Preferred Dividends (6) 0      Discontinued Items 0 -      Net Income - Reported (50) (43)      Net Income - Normalised (42) (42)     Per Share Data      EPS - Diluted (9.77) (1.56)      EPS - Basic (9.77) (1.56)      EPS - Normalised (diluted) (8.25) (1.50)      EPS - Normalised (basic) (8.25) (1.50)      Avg. Shares Outstanding - Diluted 5.1 27.9      Avg. Shares Outstanding - Basic 5.1 27.9      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

SinuNase(TM) Fast-Tracked Pivotal Phase 3 Study in Chronic Sinusitis Shows Statistically Significant Objective Evidence of Superiority of SinuNase Over Control Lavage in Severe Cases   (Accentia Biopharmaceuticals)   30-Apr-2008 Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals for Follicular Non-Hodgkin's Lymphoma   (Accentia Biopharmaceuticals)   17-Apr-2008 Accentia falls at first major hurdle   (Accentia Biopharmaceuticals)   26-Mar-2008 Accentia Biopharmaceuticals to Announce Top-Line SinuNase Phase 3 Clinical Trial Results Later Today   (Accentia Biopharmaceuticals)   24-Mar-2008 Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage   (Accentia Biopharmaceuticals)   24-Mar-2008 Event - Accentia seeking clarity   (Accentia Biopharmaceuticals)   07-Mar-2008 Accentia's CEO Provides Outlook for 2008 including Update on SinuNase Phase 3 Blinded Trial Results on 80% of Patients   (Accentia Biopharmaceuticals)   07-Jan-2008 Accentia Biopharmaceuticals Reaffirms its Confidence in the Ongoing Unblinding of the BiovaxID(TM) Phase 3 Data Based on a Track Record of Eliciting an Immune Response in 80% of Patients   (Accentia Biopharmaceuticals)   21-Dec-2007 Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma   (Accentia Biopharmaceuticals)   01-Nov-2007 Accentia Announces Results of Market Survey on Chronic Sinusitis Based on Responses From 750 ENT Specialists   (Accentia Biopharmaceuticals)   17-Oct-2007 Accentia Biopharmaceuticals Announces Unblinding and Analysis of Fast Tracked Phase 3 Trial for BiovaxID   (Accentia Biopharmaceuticals)   16-Oct-2007 Accentia Biopharmaceuticals Announces Completion of Enrollment in Fast-Tracked Pivotal Phase 3 Clinical Trial of SinuNase for Chronic Sinusitis   (Accentia Biopharmaceuticals)   08-Oct-2007 Accentia Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis   (Accentia Biopharmaceuticals)   08-Oct-2007 Data in the SinuNase Phase 3 Clinical Trial Predicts that Virtually 100% of Chronic Sinusitis Cases are Due to a Fungal-Induced Inflammation   (Accentia Biopharmaceuticals)   10-Sep-2007 Accentia Biopharmaceuticals Updates Interim Analysis of Blinded Clinical Results in the Fast-Tracked Pivotal Phase 3 Trial of SinuNase for the Treatment of Refractory Chronic Sinusitis   (Accentia Biopharmaceuticals)   15-Aug-2007 Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis   (Accentia Biopharmaceuticals)   31-Jul-2007 Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis   (Accentia Biopharmaceuticals)   28-Jun-2007 Accentia Biopharmaceuticals' Majority-Owned Subsidiary, Biovest, Receives Request from the Independent Data Monitoring Committee to Conduct Interim Analysis of Anti-Cancer Vaccine, BiovaxID   (Accentia Biopharmaceuticals)   13-Jun-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name Accentia Biopharmaceuticals AllerNase triamcinolone acetonide   BiovaxID -   Emezine prochlorperazine   Histex HC hydrocodone bitartrate, carbinoxamine maleate & pseudoephedrine   Histex I/E carbinoxamine maleate   Histex PD/Histex PD12 carbinoxamine maleate & carbinoxamine tannate   Histex SR brompheniramine & pseudoephedrine   Histex/Histex Liquid chlorpheniramine & pseudoephedrine   Neotic -   Pain Product 1 -   Pain Product 2 -   Pain Product 3 -   Respi~TANN carbetapentane & pseudoephedrine   Revimmune cyclophosphamide   SinuNase amphotericin B   Xodol hydrocodone & acetaminophen   Zinotic chloroxylenol, pramoxine & zinc acetate

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 13:51:57 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd